Literature DB >> 21346618

Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia.

Geartsje Boonstra1, Neeltje E M van Haren, Hugo G Schnack, Wiepke Cahn, Huibert Burger, Maria Boersma, Bart de Kroon, Diederick E Grobbee, Hilleke E Hulshoff Pol, René S Kahn.   

Abstract

The influence of antipsychotic medication on brain morphology in schizophrenia may confound interpretation of brain changes over time. We aimed to assess the effect of discontinuation of atypical antipsychotic medication on change in brain volume in patients. Sixteen remitted, stable patients with first-episode schizophrenia, schizoaffective or schizophreniform disorder and 20 healthy controls were included. Two magnetic resonance imaging brain scans were obtained from all subjects with a 1-year interval. The patients either discontinued (n = 8) their atypical antipsychotic medication (olanzapine, risperidone, or quetiapine) or did not (n = 8) discontinue during the follow-up period. Intracranial volume and volumes of total brain, cerebral gray and white matter, cerebellum, third and lateral ventricle, nucleus caudatus, nucleus accumbens, and putamen were obtained. Multiple linear regression analyses were used to assess main effects for group (patient-control) and discontinuation (yes-no) for brain volume (change) while correcting for age, sex, and intracranial volume. Decrease in cerebral gray matter and caudate nucleus volume over time was significantly more pronounced in patients relative to controls. Our data suggest decreases in the nucleus accumbens and putamen volumes during the interval in patients who discontinued antipsychotic medication, whereas increases were found in patients who continued their antipsychotics. We confirmed earlier findings of excessive gray matter volume decrements in patients with schizophrenia compared with normal controls. We found evidence suggestive of decreasing volumes of the putamen and nucleus accumbens over time after discontinuation of medication. This might suggest that discontinuation reverses effects of atypical medication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346618     DOI: 10.1097/JCP.0b013e31820e3f58

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  20 in total

1.  First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia.

Authors:  Kjetil N Jørgensen; Ragnar Nesvåg; Sindre Gunleiksrud; Andrea Raballo; Erik G Jönsson; Ingrid Agartz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-07       Impact factor: 5.270

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 3.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

4.  Basal ganglia and thalamic morphology in schizophrenia and bipolar disorder.

Authors:  Fay Y Womer; Lei Wang; Kathryn I Alpert; Matthew J Smith; John G Csernansky; Deanna M Barch; Daniel Mamah
Journal:  Psychiatry Res       Date:  2014-06-06       Impact factor: 3.222

5.  White matter integrity is reduced in bulimia nervosa.

Authors:  Lisa N Mettler; Megan E Shott; Tamara Pryor; Tony T Yang; Guido K W Frank
Journal:  Int J Eat Disord       Date:  2013-01-28       Impact factor: 4.861

6.  A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia.

Authors:  Eric A Nelson; Nina V Kraguljac; David M White; Ripu D Jindal; Ah L Shin; Adrienne C Lahti
Journal:  Can J Psychiatry       Date:  2020-02-05       Impact factor: 4.356

7.  Subcortical Brain Volume Abnormalities in Individuals With an At-risk Mental State.

Authors:  Daiki Sasabayashi; Yoichiro Takayanagi; Tsutomu Takahashi; Naoyuki Katagiri; Atsushi Sakuma; Chika Obara; Masahiro Katsura; Naohiro Okada; Shinsuke Koike; Hidenori Yamasue; Mihoko Nakamura; Atsushi Furuichi; Mikio Kido; Yumiko Nishikawa; Kyo Noguchi; Kazunori Matsumoto; Masafumi Mizuno; Kiyoto Kasai; Michio Suzuki
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

8.  Brain gray matter phenotypes across the psychosis dimension.

Authors:  Elena I Ivleva; Anup S Bidesi; Binu P Thomas; Shashwath A Meda; Alan Francis; Amanda F Moates; Bradley Witte; Matcheri S Keshavan; Carol A Tamminga
Journal:  Psychiatry Res       Date:  2012-10-30       Impact factor: 3.222

9.  Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia.

Authors:  Berend Malchow; Alkomiet Hasan; Thomas Schneider-Axmann; Alexander Jatzko; Oliver Gruber; Andrea Schmitt; Peter Falkai; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-02       Impact factor: 5.270

10.  Heritability of multivariate gray matter measures in schizophrenia.

Authors:  Jessica A Turner; Vince D Calhoun; Andrew Michael; Theo G M van Erp; Stefan Ehrlich; Judith M Segall; Randy L Gollub; John Csernansky; Steven G Potkin; Beng-Choon Ho; Juan Bustillo; S Charles Schulz; Lei Wang
Journal:  Twin Res Hum Genet       Date:  2012-06       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.